AstraZeneca (AZ) has shared “unprecedented” overall survival (OS) results from a late-stage study of Imfinzi (durvalumab) ...

GSK has shared positive headline results for its mRNA seasonal influenza vaccine and outlined that it will now progress the ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

We're celebrating Healthcare Simulation Week 2024 by highlighting the transformative power of our multi-award-winning medical ...

GSK’s “ultra-long-acting” biologic depemokimab has demonstrated a significant reduction in severe asthma exacerbations over ...

Syneos Health Communications and Precision AQ led the agency list, while Novartis, Roche and Takeda shared the top client ...

Novartis’ Fabhalta (iptacopan) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic ...

Moderna’s JN.1-adapted COVID-19 vaccine has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in adults and children aged six months and older. The adaption ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Pfizer and Valneva have shared promising immune response and safety results from a mid-stage study of their Lyme disease vaccine candidate. The phase 2 VLA15-221 trial randomised healthy participants ...

Eli Lilly and HAYA Therapeutics have entered into a multi-year agreement worth up $1bn to discover regulatory genome targets for obesity and related metabolic conditions. The collaboration centres ...